LightPath Technologies, Inc. — Form 10-Q Summary
Reporting period: The filing covers the quarter and nine months ended March 31, 2024—LightPath’s fiscal third quarter of 2024. The request metadata says “2023 Q3,” but the filing period is 2024 Q3. LightPath manufactures optical components, assemblies and engineered optical solutions, with operations in the United States, China and Latvia. It acquired thermal-imaging engineering firm Visimid in July 2023.
Financial Results and Liquidity
| Metric | Three months ended March 31, 2024 | Nine months ended March 31, 2024 |
|---|---|---|
| Revenue | $7.70 million, up 4% year over year | $23.09 million, down 1% |
| Gross margin | $1.61 million; 21% of revenue, versus 34% | $6.11 million; 26% of revenue, versus 34% |
| Operating loss | $2.58 million, versus $0.96 million | $5.62 million, versus $2.75 million |
| Net loss | $2.60 million, or $0.07 per share | $5.65 million, or $0.15 per share |
| EBITDA (non-GAAP) | Loss of $1.51 million, versus $0.24 million | Loss of $2.40 million, versus $0.43 million |
For the nine months, operating cash flow was positive $456,000, compared with cash used of $921,000 in the prior-year period. Investing used $2.38 million and financing used $2.07 million. Cash, cash equivalents and restricted cash totaled $3.16 million at March 31, 2024, down $3.99 million from June 30, 2023; unrestricted cash was $3.01 million and restricted cash $150,000.
Working capital was approximately $7.8 million. Total assets were $49.71 million and total liabilities $18.00 million. Loans payable were approximately $599,000 at quarter-end; the BankUnited term loan had been paid off in February 2024, and the $150,000 ANBTX note was repaid May 2, 2024. Lease liabilities totaled approximately $10.15 million. The filing states that the company may need additional capital if sales, costs or strategic investment needs develop unfavorably.
Material Changes and Management Commentary
- Quarterly revenue growth reflected higher infrared-component and engineering-services sales. For the nine-month period, infrared components rose 15% and engineering services rose 213%, while visible components fell 21%; assemblies and modules were approximately flat.
- Gross margin declined substantially. Management attributed the pressure primarily to a greater mix of lower-margin infrared components versus visible products and a larger-than-usual quarterly inventory revaluation write-down, related to cost-reduction efforts.
- Operating expenses increased, including higher SG&A, product development and amortization. Management cited added Visimid personnel and acquisition-related amortization; quarterly SG&A also included legal and professional fees related to the rescheduled annual meeting and Delaware Chancery Court proceedings.
- Backlog was approximately $22.0 million at March 31, 2024, down 17% from $26.6 million a year earlier and up 1% from fiscal year-end. Management cited shipments against prior orders, partially offset by an international military-program renewal and a Visimid contract awarded by Lockheed Martin.
- Management is shifting toward engineered solutions and assemblies. It expects engineering-services activity to support that strategy, but does not expect significant near-term growth in visible components.
Outlook, Risks and Unusual Items
- No specific financial guidance or quantified revenue outlook is provided. Management expects existing annual and multi-year contracts to renew, but renewal timing can cause backlog and revenue fluctuations.
- LightPath did not renew its usual annual Germanium-optics order from a major customer during the fiscal second quarter. It says it is working with customers to transition to its proprietary BlackDiamond materials. The transition may take time and could temporarily reduce revenue and backlog; Germanium and Gallium export restrictions and supply concentration add uncertainty.
- Management cited weak Chinese demand and the possibility that a further China economic slowdown could materially harm results. The filing also identifies geopolitical risks, including the Russia-Ukraine and Israel-Hamas conflicts, and potential supplier, inflation, interest-rate and cost pressures.
- The nine-month results included $190,000 of recovered funds associated with alleged misappropriation by former Chinese management. Management expects minimal further related legal and consulting expense. It says pending proceedings are not expected to have a material adverse effect.
- The Visimid acquisition’s purchase-price allocation remains provisional pending valuation work. The filing reports approximately $2.7 million of total purchase price, net of acquired cash and including estimated earnout, and notes that goodwill and intangible-asset values may change.
- Shares outstanding were 38,126,249 at March 31, 2024 and 38,807,432 as of May 6, 2024. The filing reports effective disclosure controls and no material change in internal control over financial reporting during the nine-month period.
Important Facts for Investors to Verify
- Whether the gross-margin decline and inventory revaluation are temporary, and whether margins recover as product mix and cost-reduction efforts evolve.
- Timing and value of Germanium-order renewals or BlackDiamond conversions, and whether those transitions restore backlog and sales.
- Cash availability and funding needs, including the portion held overseas, repatriation limits, ongoing capital spending and remaining lease commitments.
- Visimid’s contribution to revenue, profitability and backlog, as well as final acquisition valuations and any earnout obligations.
- Backlog conversion and customer contract timing, particularly for defense programs, Lockheed Martin work and China-related demand.
- Potential dilution from equity issuance and share-based awards, alongside the company’s continuing operating losses.